Next Science (ASX:NXS) - Outgoing CEO and Managing Director, Judith Mitchell
Outgoing CEO and Managing Director, Judith Mitchell
Source: Next Science
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Next Science (NXS) appoints Harry Thomas Hall IV (I.V.) as its newest Managing Director and Chief Executive Officer
  • I.V. has worked in the global medical device industry, holding a number of roles across product development, global strategic marketing, commercial operations and sales leadership
  • I.V. will commence in the role on July 10, while current CEO Judith Mitchell remains with the company until the end of July to ensure a smooth leadership transition
  • Shares rose 4.72 per cent to 55.5 cents at midday AEST

Next Science (NXS) has appointed Harry Thomas Hall IV (I.V.) as its newest Managing Director and Chief Executive Officer.

I.V. will begin in the role from July 10, on a total fixed remuneration contract of US$450,000 (A$653,000) per annum.

For more than 25 years, I.V. has worked in the global medical device industry, holding a number of roles across product development, global strategic marketing, commercial operations and sales leadership.

He is also the president of Trauma, Extremities, Craniomaxillofacial and Animal Health, responsible for the global portfolio and execution strategy for a US$3.2 billion platform (A$4.64 billion).

“I.V. is a respected leader in the healthcare industry marrying a rare blend of scientific, clinical and commercial skill and experience,” Next Science Chair Professor Mark Compton AM said.

“I.V. has a proven track record in building successful businesses, and just as importantly, a successful organisational culture.”

Mr Compton also thanked outgoing CEO Judith Mitchell for her contribution to the company and its development of XBIO.

“Judith has built a strong presence for Next Science in the US in particular, led the company through its ASX listing and built a team focused on commercial success,” Mr Compton said.

Next Science is now focusing on commercialising its XBIO technology which aim to reduce the impact of biofilm-based infections.

Judith Mitchell will remain with the company until the end of July to aid in a smooth handover.

Shares in NXS rose 4.72 per cent to 55.5 cents at midday AEST.

NXS by the numbers
More From The Market Online
The Market Online Video

Market Close: ASX200 takes a slide into the weekend

The ASX200 shed 0.85% today – with every sector – except materials, losing ground. IT stocks…

Week 20 Wrap: EU-to-China cargoes up 12% YTD; US CPI tame

US inflation was the biggest data drop of the week; Anglo American is restructuring to fend…
The Market Online Video

Market Update: ASX dips with only materials afloat

The ASX is down nearly half a per cent - on par with future's predictions -…

Patagonia grows portfolio of REE and lithium-focused territory with exploration grants

Patagonia Lithium Ltd has been granted an additional 15 exploration licences in Argentina where it is…